Nucor earnings beat by $0.08, revenue fell short of estimates
In a recent transaction, Shana Carol Neal, Executive Vice President and Chief People Officer at Becton Dickinson & Co. (NYSE:BDX), sold 788 shares of the company's common stock. The shares were sold on January 7, 2025, at a price of $235.00 each, amounting to a total sale value of $185,180. This transaction was conducted under a pre-established Rule 10b5-1 trading plan.
The filing also highlighted other transactions, including multiple acquisitions of shares at no cost through the company's deferred compensation plan. These transactions were not sales and did not involve any cash exchange. For deeper insights into BDX's valuation metrics and financial health indicators, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US equities. For deeper insights into BDX's valuation metrics and financial health indicators, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US equities.
The filing also highlighted other transactions, including multiple acquisitions of shares at no cost through the company's deferred compensation plan. These transactions were not sales and did not involve any cash exchange.
In other recent news, Becton Dickinson (BD), a leading medical technology firm, reported robust growth in its fourth quarter and full-year fiscal 2024 earnings call. The company experienced a 7.4% revenue growth in Q4 and a 5% full-year organic revenue increase. BD's adjusted diluted earnings per share (EPS) also rose by 11.4%, reaching $13.14 for the full year. Despite challenges in the Chinese market and the Bioscience-Pharma sector, BD's MedTech and Diagnostics segments reported a growth of 5.9%.
Additional highlights include BD Medical (TASE:PMCN)'s biologic drug delivery sales surpassing $1 billion and the announcement of a $1 billion share repurchase plan. The company also increased its dividend by 9.5%. As part of recent developments, BD anticipates revenue between $21.9 billion and $22.1 billion for FY '25, with adjusted diluted EPS guidance of $14.25 to $14.60.
Despite expecting a mid-single-digit decline in the Chinese market, BD remains optimistic about future growth. The company is focusing on innovations in biologics and diagnostics, and the integration of the Advanced Patient Monitoring business to drive growth. However, it is worth noting that the first quarter performance is anticipated to be below the overall guidance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.